Regulatory approval
Published by the Health Canada. Approved
VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Abemaciclib | |
| HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib | |
| HC (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib | |
| HC (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Exemestane | |
| HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Abemaciclib, Exemestane | |
| HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Exemestane |